Skip to main content

Table 1 Characteristics of enrolled patients

From: Effect of the duration of the capecitabine regimen following colon cancer surgery in an elderly population: a retrospective cohort study

Characteristics Postoperative capecitabine duration P value
0  ≤ 12 weeks  ≤ 24 weeks
No. of participants 143 79 35  
  Age (years), mean (SD) 77.69 (4.90) 73.57 (2.77) 73.34 (2.99)  < 0.001
   ≥ 70, < 75 43 (30.07%) 46 (58.23%) 25 (71.43%)  
   ≥ 75, < 80 43 (30.07%) 33 (41.77%) 8 (22.86%)  
   ≥ 80 57 (39.86%) 0 (0.00%) 2 (5.71%)  
Gender, N (%)     0.421
  Male 85 (59.44%) 54 (68.35%) 22 (62.86%)  
  Female 58 (40.56%) 25 (31.65%) 13 (37.14%)  
T stage, N (%)     0.177
  1–2 8 (5.59%) 2 (2.53%) 1 (2.86%)
  3 118 (82.52%) 68 (86.08%) 25 (71.43%)
  4 17 (11.89%) 9 (11.39%) 9 (25.71%)  
N stage, N (%)     0.832
  0 74 (51.75%) 36 (45.57%) 18 (51.43%)
  1 57 (39.86%) 33 (41.77%) 14 (40.00%)
  2 12 (8.39%) 10 (12.66%) 3 (8.57%)
Stage, N (%)     0.664
  II 74 (51.75%) 36 (45.57%) 18 (51.43%)
  III 69 (48.25%) 43 (54.43%) 17 (48.57%)
Histological type     0.883
  Common type 122 (85.31%) 68 (86.08%) 31 (88.57%)  
  Special typea 21 (14.69%) 11 (13.92%) 4 (11.43%)  
CA199, N (%)     0.232
  Normal 122 (85.31%) 60 (76.92%) 27 (77.14%)  
  Elevated 21 (14.69%) 18 (23.08%) 8 (22.86%)  
CEA, N (%)     0.830
  Normal 92 (64.34%) 48 (60.76%) 23 (65.71%)  
  Elevated 51 (35.66%) 31 (39.24%) 12 (34.29%)  
MMR status     0.021
  dMMR 15 (10.49%) 3 (3.80%) 2 (5.71%)  
  pMMR 106 (74.13%) 51 (64.56%) 28 (80.00%)  
  Unknown 22 (15.38%) 25 (31.65%) 5 (14.29%)  
  Charlson comorbidity index      < 0.001
   ≤ 4 88 (61.54%) 75 (94.94%) 34 (97.14%)  
   > 4 55 (38.46%) 4 (5.06%) 1 (2.86%)  
  1. Notes: aSpecial type adenocarcinoma includes mucinous, signet ring cell, medullary, and undifferentiated variants
  2. Abbreviations: CA carcinoma antigen; CEA carcinoembryonic antigen; MMR mismatch repair; dMMR mismatch repair deficiency; pMMR proficient mismatch repair